SEATTLE, Washington, JUNE 27, 2011 The Life Sciences Discovery Fund (LSDF) today announced awards to three multi-institutional teams to support development of improved therapies and key resources for medical researchers and health-care policymakers. LSDF will allocate up to $8 million among the three programs.
The programs will be led by University of Washington investigators in partnership with collaborators across the state. Dr. David Flum will work with health-care providers, insurers, and information technology experts to create databases of clinical practices, patient outcomes, and medical costs that can be used to assess the comparative effectiveness and cost effectiveness of specific health-care strategies. This work builds upon an LSDF project grant that Dr. Flum received in 2007.
A second program, led by Dr. Michael Schwartz, will develop new human stem cell-based treatments for type 1 diabetes that avoid the problems of tumor formation and immune rejection that have previously limited the use of such therapies. The research team anticipates that their treatment approach can ultimately be applied to other diseases.
The third program, directed by Dr. John Slattery, will establish a system for collection and statewide distribution of human biological specimens required to answer important research questions and ultimately improve disease diagnosis and treatment. The specimens will be linked to biologically relevant data on the donors, and the program will be constructed to protect patient privacy and rights. This program will complement the cancer biospecimen resource that Dr. Peggy Porter of the Fred Hutchinson Cancer Research Center is developing under an LSDF 2009 program grant.
The three awards were made in the 2010 program grant competition, which supports the launch of new collaborative initiatives that address major health problems and position organizations for future competitiveness and leadership.
|Contact: Alden Jones|
Life Sciences Discovery Fund